In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits | With a $2.2 billion ...
GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also chalking up wins in the US.
Shares in GSK fell around 9% this morning after ... of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial. Judge Vivian Medinilla of Delaware Superior Court issued an ...
Hosted on MSN18d
Is it game over for the GSK share price?The overhanging Zantac litigation case has dented investor confidence ... It’s a FTSE 100 pharmaceutical flop GSK has posted a string of drug trial wins lately. Its specialty medicines division saw ...
who did not know that GSK had for decades concealed an internal study that implicated GSK's liability to Zantac users. When the true details entered the market, the lawsuit claims that investors ...
who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users; and (4) as a result, Defendants’ positive statements about the ...
who did not know that GSK had for decades concealed an internal study that implicated the company's liability to Zantac users.' While GSK remains focused on its ambitious 2031 revenue target ...
who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users; and (4) as a result, Defendants’ positive statements about the ...
who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users; and (4) as a result, Defendants’ positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback